Literature DB >> 26574016

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Jean-Philippe Lanoix1, Thomas Ioerger2, Aimee Ormond3, Firat Kaya4, James Sacchettini2, Véronique Dartois4, Eric Nuermberger5.   

Abstract

Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line antituberculosis regimen. Its activity is strongly pH dependent; the MIC changes by several orders of magnitude over a range of pH values that may be encountered in various in vivo compartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice with large caseous lung lesions. In the present study, we evaluated whether such inactivity was explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants. Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid, and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the total population in nonresponding C3HeB/FeJ mice. The selective inactivity of PZA in large caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26574016      PMCID: PMC4750710          DOI: 10.1128/AAC.01370-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Mechanism of softening of tubercles. III. Hydrolysis of protein and nucleic acid during anaerobic autolysis of normal and tuberculous lung tissue in vitro.

Authors:  C WEISS; J TABACHNICK; H P COHEN
Journal:  AMA Arch Pathol       Date:  1954-03

Review 2.  The near future: improving the activity of rifamycins and pyrazinamide.

Authors:  D A Mitchison; P B Fourie
Journal:  Tuberculosis (Edinb)       Date:  2010-04-09       Impact factor: 3.131

3.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.

Authors:  Jamie Harper; Ciaran Skerry; Stephanie L Davis; Rokeya Tasneen; Mariah Weir; Igor Kramnik; William R Bishai; Martin G Pomper; Eric L Nuermberger; Sanjay K Jain
Journal:  J Infect Dis       Date:  2011-12-23       Impact factor: 5.226

5.  A multidrug-resistant, acr1-deficient clinical isolate of Mycobacterium tuberculosis is unimpaired for replication in macrophages.

Authors:  Juliano Timm; Natalia Kurepina; Barry N Kreiswirth; Frank A Post; Gabrielle B Walther; Helen C Wainwright; Linda-Gail Bekker; Gilla Kaplan; John D McKinney
Journal:  J Infect Dis       Date:  2006-05-11       Impact factor: 5.226

6.  Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Authors:  Joaquín Rullas; Juan Ignacio García; Manuela Beltrán; Pere-Joan Cardona; Neus Cáceres; José Francisco García-Bustos; Iñigo Angulo-Barturen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

7.  [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].

Authors:  J Grosset; C Truffot; J Fermanian; H Lecoeur
Journal:  Pathol Biol (Paris)       Date:  1982-06

8.  Genetic Manipulation of Mycobacterium tuberculosis.

Authors:  Michelle H Larsen; Karolin Biermann; Steven Tandberg; Tsugunda Hsu; William R Jacobs
Journal:  Curr Protoc Microbiol       Date:  2007-08

9.  Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Authors:  Deepak V Almeida; Sandeep Tyagi; Si-Yang Li; Kristina Wallengren; Alexander S Pym; Nicole C Ammerman; William R Bishai; Jacques H Grosset
Journal:  Mycobact Dis       Date:  2014-05-05

10.  Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell.

Authors:  Shumin Tan; Neelima Sukumar; Robert B Abramovitch; Tanya Parish; David G Russell
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

View more
  39 in total

1.  Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Authors:  Vikram Saini; Nicole C Ammerman; Yong Seok Chang; Rokeya Tasneen; Richard E Chaisson; Sanjay Jain; Eric Nuermberger; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Authors:  Claire M Naftalin; Rupangi Verma; Meera Gurumurthy; Qingshu Lu; Matthew Zimmerman; Benjamin Chaik Meng Yeo; Kin Hup Tan; Wenwei Lin; Buduo Yu; Véronique Dartois; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 3.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 4.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

5.  Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Authors:  Nicole C Ammerman; Rosemary V Swanson; Elaine M Bautista; Deepak V Almeida; Vikram Saini; Till F Omansen; Haidan Guo; Yong Seok Chang; Si-Yang Li; Asa Tapley; Rokeya Tasneen; Sandeep Tyagi; Fabrice Betoudji; Chivonne Moodley; Bongani Ngcobo; Logan Pillay; Linda A Bester; Sanil D Singh; Richard E Chaisson; Eric Nuermberger; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

6.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

Review 7.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

8.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

9.  High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Rokeya Tasneen; Paul O'Brien; Jansy Sarathy; Hassan Safi; Michael Pinn; David Alland; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.

Authors:  Jean-Philippe Lanoix; Fabrice Betoudji; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.